{
  "id": "5c5f29a81a4c55d80b00001f",
  "type": "factoid",
  "question": "What is the indication for Truvada?",
  "ideal_answer": "Truvada is used for HIV pre-exposure prophylaxis (PrEP) in high risk individuals",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23226529",
    "http://www.ncbi.nlm.nih.gov/pubmed/24223514",
    "http://www.ncbi.nlm.nih.gov/pubmed/21632769",
    "http://www.ncbi.nlm.nih.gov/pubmed/19731560",
    "http://www.ncbi.nlm.nih.gov/pubmed/29902179",
    "http://www.ncbi.nlm.nih.gov/pubmed/22581627",
    "http://www.ncbi.nlm.nih.gov/pubmed/29068302",
    "http://www.ncbi.nlm.nih.gov/pubmed/22874836",
    "http://www.ncbi.nlm.nih.gov/pubmed/26411737",
    "http://www.ncbi.nlm.nih.gov/pubmed/27093238",
    "http://www.ncbi.nlm.nih.gov/pubmed/26270298",
    "http://www.ncbi.nlm.nih.gov/pubmed/28276922"
  ],
  "snippets": [
    {
      "text": "pre-exposure prophylaxis (PrEP) and the recent approval by the FDA of the supplemental indication for Truvada as PrEP",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24223514",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " tenofovir disoproxil fumarate 300 mg (TDF)/emtricitabine 200 mg (FTC) (Truvada, Gilead Sciences) as antiretroviral preexposure prophylaxis (PrEP) to reduce the risk for HIV acquisition ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22874836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In January 2011, following publication of evidence of safety and efficacy of daily oral tenofovir disoproxil fumarate 300 mg (TDF)/emtricitabine 200 mg (FTC) (Truvada, Gilead Sciences) as antiretroviral preexposure prophylaxis (PrEP) to reduce the risk for HIV acquisition among MSM in the iPrEx trial, CDC issued interim guidance to make available information and important initial cautions on the use of PrEP in this population. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22874836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this commentary, we review literature on sexual behavior change accompanying PrEP use, discuss risk compensation concerns and the &amp;quot;Truvada whore&amp;quot; stereotype as PrEP barriers, question the appropriateness of restricting PrEP access because of risk compensation, and consider sexual pleasure as a benefit of PrEP, an acceptable motive for seeking PrEP, and a core element of health. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26270298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nDaily pre-exposure prophylaxis (PrEP) with Truvada (a combination of emtricitabine (FTC) and tenofovir (TFV) disoproxil fumarate (TDF)) is a novel HIV prevention strategy recently found to prevent HIV transmission in men who have sex with men and heterosexual couples.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23226529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Its co-formulation with emtricitabine (Truvada) is particularly convenient for treating both HIV and HBV in co-infected individuals.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19731560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In January 2011, following publication of evidence of safety and efficacy of daily oral tenofovir disoproxil fumarate 300 mg (TDF)/emtricitabine 200 mg (FTC) (Truvada, Gilead Sciences) as antiretroviral preexposure prophylaxis (PrEP) to reduce the risk for HIV acquisition among MSM in the iPrEx trial, CDC issued interim guidance to make available information and important initial cautions on the use of PrEP in this population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22874836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Truvada (emtricitabine-tenofovir) is currently the only medication approved for PrEP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29902179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Daily pre-exposure prophylaxis (PrEP) with Truvada (a combination of emtricitabine (FTC) and tenofovir (TFV) disoproxil fumarate (TDF)) is a novel HIV prevention strategy recently found to prevent HIV transmission in men who have sex with men and heterosexual couples.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23226529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antiretroviral preexposure prophylaxis (PrEP; emtricitabine and tenofovir disoproxil fumarate [Truvada]) prevents HIV without penalizing sexual pleasure, and may even enhance pleasure (e.g., by reducing HIV-related anxiety).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26270298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The pre-exposure prophylaxis (PrEP) drug Truvada is a new HIV prevention technology that is predominantly promoted as relevant to HIV-negative gay men.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28276922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION The FEM-PrEP trial was a pre-exposure prophylaxis clinical trial to test the safety and efficacy of Truvada (tenofovir disoproxil fumarate and emtricitabine) in the prevention of human immunodeficiency virus infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26411737",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oral pre-exposure prophylaxis (PrEP) using the antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) has been shown to dramatically reduce the risk of HIV acquisition for women at higher risk of infection if taken daily.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27093238",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Third, Truvada can be used prophylactically to prevent transmission of HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581627",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daily preexposure prophylaxis (PrEP) with Truvada (emtricitabine FTC and tenofovir disoproxil fumarate TDF) is a novel HIV prevention strategy recently found to reduce HIV incidence among men who have sex with men.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21632769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is the only drug approved to prevent HIV infections, and Truvada is the key pharmaceutical component of pre-exposure prophylaxis, which is aimed at preventing, rather than treating, HIV infection and transmission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29068302",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daily pre-exposure prophylaxis (PrEP) with Truvada (a combination of emtricitabine (FTC) and tenofovir (TFV) disoproxil fumarate (TDF)) is a novel HIV prevention strategy recently found to prevent HIV transmission in men who have sex with men and heterosexual couples.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23226529",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Prevention of HIV infection"
}